The multi-method, longitudinal, prospective cohort study identified appropriate cardiovascular biomarkers and engaged 200 patients with stable ischemic heart disease (IHD).
Lifestyle choices such as smoking, poor nutrition, and physical inactivity increase the risk of IHD. This type of heart disease is the leading killer in the United States in men and women of all ethnicities. For those already diagnosed with the condition, secondary prevention is managed within clinical environments. It focuses on the control of cholesterol, blood pressure, and diabetes.
The risk calculator for atherosclerosis cardiovascular disease is one that helps predict cardiovascular events. It considers factors such as race, sex, age, blood cholesterol and pressure, smoking status, and diabetes. Such tests are only performed during hospital or clinic visits. The tests help to prevent disastrous situations, improve healthcare access, and lower resource utilization.
The objectives of the Prediction, Risk, and Evaluation of Major Adverse Cardiac Events (PRE-MACE) study included:
Estimating the cross-sectional links between the recognized main adverse cardiovascular occurrence (MACE) intermediate biomarkers
Discovering the longitudinal capability of remote physiological and biochemical monitoring to forecast changes in MACE intermediate biomarkers
Determining the ability of remote monitoring and biomarkers to forecast incident MACE at starting point and after 12 months
Conducting exploration proteomics and lipidomics aimed at increasing the potential circulating prognostic MACE biomarkers
Measuring the cost-effectiveness or budget-friendliness of remote monitoring for latent MACE biomarkers and MACE itself
The PRE-MACE learning is aimed at evaluating feasibility regarding adherence and pilot remote monitoring with biosensors, and biomarkers. The study actively used patient-reported outcomes (PROs) to obtain continuous insight of participants in real-time situations.
The study relied on Mitra® devices for remote biochemical biomarker monitoring. The remote blood microsampling enhances longitudinal, and volumetric blood sample collection via simple finger pricks that study participants can do at home.
The Mitra device with patented VAMS® technology has an absorbent polymeric tip that uptakes blood in a fixed volume (10 µL). This precision enhances sample heterogeneity and overcomes hematocrit bias challenges that are common with dried blood spot (DBS) collection. The study used automated email reminders or push notifications to remind participants to make their scheduled blood draws.
This study is just one of the numerous smarter healthcare practices being advanced by clinicians worldwide. Microsampling allows for volunteers to participate in clinical trials remotely and for longer periods. It makes the studies more flexible and convenient for both the clinicians and the study volunteers. Microsampling could be just what your research needs to get to the next level.
Image Credits: iStock, Trajan Scientific and Medical